view more →
Aer Therapeutics is a clinical stage biopharmaceutical company developing a novel inhaled approach to treat lung disease with excess mucus and mucus plugs.
view more →
Altis has developed a patent-pending stem cell technology recreating the human intestinal epithelium for compound screening and microbiome research.
view more →
AN2 is a biopharmaceutical company focused on developing novel medicines. IPO in March 2022 (NASDAQ: ANTX)
view more →
Axonis Therapeutics is a Boston-based, neuro-focused biotechnology company developing first- and best-in-class medicines targeting KCC2.
view more →
(BITT) is a Boston-based biopharmaceutical company developing immune-based approaches for the treatment of cancer and infectious diseases.
view more →
Manufacturer of late-stage clinical biopharmaceutical products. IPO in June, 2016 (NASDAQ:CLSD).
view more →
The company’s small-molecule therapies focus on cyclin-dependent kinases and CDKs. IPO in May 2017 (NASDAQ: GTHX).
view more →
Developer of injectable controlled release technologies designed to reduce the frequency of dosing for ocular therapies. IPO in September 2020 (NASDAQ: GRAY).
view more →
Kymera is developing a heterobifunctional small molecule drug platform. IPO in August 2020 (NASDAQ: KYMR).
view more →
Developer of innovative neurodegeneration small-molecules intended to establish a platform for novel drug discovery.Acquired by Bial in October 2020.
view more →
Operator of a biopharmaceutical agency intended to offer drugs for the treatment of diabetes and other metabolic disorders.
view more →
The Company’s lead product candidate, PB2452, is a novel reversal agent for the antiplatelet drug ticagrelor. IPO in October, 2018 (NASDAQ:PHAS)
view more →
Perfuse Therapeutics, Inc. is a seed stage biotechnology company focusing on improving retinal perfusion
view more →
A developer of multiple antibiotic drugs intended to combat antimicrobial resistance. Acquired by Shionogi 2023
view more →
The SHAPE-MaP technology developed in the lab of Dr. Weeks identifies functional motifs within RNA by mapping the RNA three-dimensional structure.
view more →
Developer of epigenetic drugs intended to be used for the treatment of cognitive disorders and diseases of the brain. Acquired by NASDAQ: ALKS in Nov 2019
view more →
Shattuck Labs is a clinical-stage biotechnology company for the treatment of cancer and autoimmune disease. IPO in October 2020 (NASDAQ: STTK)
view more →
Stridebio is developing engineered viral vectors for gene therapy. Acquired by Ginkgo Bioworks 2023
view more →
Ten63 Therapeutics is focused on improving human health by developing better, more durable therapeutics against cancer and some of the world’s most lethal diseases.
view more →
Developer of novel engineered compounds designed to corneal dystrophies, improve human health and create new therapies using drugs developed with protein engineering.
view more →
Developer of therapies based on metalloenzyme chemistry and biology platform. Acquired by NovaQuest Capital Management in January 2018.
view more →
Vigil Neuroscience is the world’s first microglia-focused therapeutics company. IPO in January 2022 (NASDAQ: VIGL). Acquired by Sanofi in 2025.
